Dr. Campbell joined Axial Therapeutics in 2017 as vice president of R&D and was promoted to CEO in February 2021. During his 28-year career, Dr. Campbell has held various leadership roles at biopharmaceutical and chemical manufacturing companies. At Ancora Pharmaceuticals, a synthetic vaccine company, Dr. Campbell served as vice president of R&D, successfully triaging the company through its acquisition by CordenPharma. At Surface Logix and Insmed, he held senior R&D management positions and played an integral role in the discovery and development of five clinical drug candidates, including the Rho kinase inhibitor belumosudil (Rezurock™) and TAK- 607 (rIGF-1/BP-3). He earned his PhD in chemistry from Queen’s University (Canada) in 1992. He conducted post-doctoral research in natural product synthesis at Duke University during which he completed the first total synthesis of the Thy-1 GPI membrane anchor. To date, Dr. Campbell has co-authored 19 publications and is co- inventor on 23 issued patents.